Skip to main content
Premium Trial:

Request an Annual Quote

Flagship Biosciences: Gina Wallar

Gina Wallar has been appointed as chief commercial officer of Flagship Biosciences. She joins the spatial biology and biomarker analytics services firm from Fulgent Genetics, where she was senior VP of sales and business development. Prior to that, she held various positions at NeoGenomics Laboratories, most recently president of pharma services, and before that she was director at LabCorp Clinical Trials in Los Angeles. Wallar holds a PhD in molecular epidemiology from the University of California, Los Angeles and an MPH in epidemiology and biostatistics from Boston University.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.